about
Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcomeAnti-citrullinated protein antibodies cause arthritis by cross-reactivity to joint cartilage.Four Anti-dsDNA Antibody Assays in Relation to Systemic Lupus Erythematosus Disease Specificity and Activity.Dynamic Response Genes in CD4+ T Cells Reveal a Network of Interactive Proteins that Classifies Disease Activity in Multiple Sclerosis.Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort studyChanges in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.Circulating secretory IgA antibodies against cyclic citrullinated peptides in early rheumatoid arthritis associate with inflammatory activity and smoking.Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA projectAssociations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish register.Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts.Immunoglobulin (Ig)G1 and IgG4 anti-cyclic citrullinated peptide (CCP) associate with shared epitope, whereas IgG2 anti-CCP associates with smoking in patients with recent-onset rheumatoid arthritis (the Swedish TIRA project).Decrease in bone mineral density during three months after diagnosis of early rheumatoid arthritis measured by digital X-ray radiogrammetry predicts radiographic joint damage after one year.Genetic Variants of the NLRP3 Inflammasome Are Associated with Stroke in Patients with Rheumatoid Arthritis.CARD8 p.C10X polymorphism is associated with inflammatory activity in early rheumatoid arthritis.Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy.A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis.IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis.Fcγ receptor type IIIA genotype and response to tumor necrosis factor α–blocking agents in patients with rheumatoid arthritisGenetic variants inCARD8but not inNLRP3are associated with ankylosing spondylitisGenetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (The Swedish TIRA project)The 158V polymorphism of Fc gamma receptor type IIIA in early rheumatoid arthritis: increased susceptibility and severity in male patients (the Swedish TIRA project)Beware of antibodies to dietary proteins in "antigen-specific" immunoassays! falsely positive anticytokine antibody tests due to reactivity with bovine serum albumin in rheumatoid arthritis (the Swedish TIRA project)IgG rheumatoid factors against the four human Fc-gamma subclasses in early rheumatoid arthritis (the Swedish TIRA project)Associations with smoking and shared epitope differ between IgA- and IgG-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritisAssociation of serum C-reactive protein levels with lupus disease activity in the absence of measurable interferon-α and a C-reactive protein gene variantChanges in anti-citrullinated protein antibody isotype levels in relation to disease activity and response to treatment in early rheumatoid arthritisStructural Basis of Cross-Reactivity of Anti-Citrullinated Protein AntibodiesImmunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual
P50
Q33778661-178D1D14-3C35-4ADF-91AC-B5D44E93FB89Q33877817-EBFE9FC8-977B-4535-AC98-B4B2492F03D6Q34462918-472ACC08-9609-43DD-9F9A-4C695704810DQ36132325-5A47E62C-86CF-461D-BAA6-E988083FA5CBQ36307076-08EEBCCA-4436-4F31-BB86-A9229EA9D552Q36577396-CFED8065-F15A-46D7-AF0E-391F8708DDE8Q36929564-2714519C-D0C5-4698-9F1A-4F5762701654Q36955351-0FF15239-8753-46F7-81D9-1E6544A3E66CQ37256378-65BF7B23-1C4D-45B9-8A1D-E026E12F9FDCQ37470470-D830DBD7-0085-4D9C-9BDE-AD0370FF4915Q39177930-C6262CFD-A2F5-48F3-9DFE-FDCAC76B8193Q40501745-EF5A100D-8D7A-4ADF-BDBD-E80C368D5761Q41583910-F8E57CDD-0DB9-4046-97D2-026C31BDF400Q47797398-9D97E2FE-3F8E-44CD-AFA4-AF28A13FFBA8Q48138068-6B446387-7694-438C-B603-6B7B2CAAD5D5Q50788255-0E5760A9-7297-494A-A3C0-B9292AC79D63Q52889310-0AE63E53-2203-4999-8177-3292C6933E80Q57537204-A117A70F-A17B-4B1C-9429-72C9AA827C29Q57623459-8EBA76EB-682B-4A38-85CD-A77E26BF3573Q59727743-708AEB99-EE03-4977-8458-CBD33A9A4574Q81926507-0C0466AA-55EF-4D14-A1D0-022114F10FCBQ82263299-8232BEA7-6853-4EC1-9E04-4E69B664F6B9Q84942817-1C8575C9-64F8-41E5-9BE6-4390E0C37E1DQ87196887-84A2CA0F-1376-44ED-ABE9-E326D172A891Q87367907-C23286CA-B0F7-4918-A254-90F198AA7080Q91095026-3203A2D5-8036-4524-B747-BB385402D4DAQ91173509-1036EB72-27AB-4711-B0BE-C945B9342EFDQ91405897-3C0E9575-EBFF-408B-A7BB-D786584066EB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alf Kastbom
@ast
Alf Kastbom
@en
Alf Kastbom
@es
Alf Kastbom
@nl
type
label
Alf Kastbom
@ast
Alf Kastbom
@en
Alf Kastbom
@es
Alf Kastbom
@nl
altLabel
Kastbom A
@en
prefLabel
Alf Kastbom
@ast
Alf Kastbom
@en
Alf Kastbom
@es
Alf Kastbom
@nl
P106
P1153
12788610100
P31
P496
0000-0001-7187-1477